Co-Op, Immuno-Oncology Research
Moderna
Summary
This is a full-time co-op based in Cambridge, MA from January 18, 2027 – June 25, 2027. Candidates must be available for the entire duration of the program. Immuno-Oncology Research at Moderna is seeking a talented and motivated co-op to join our efforts supporting the development of new mRNA-based drugs for cancer therapy.
Job description
Here's What You'll Do
- Partner with experienced Immuno-Oncology lab scientists to learn and apply core cell and molecular biology techniques.
- Learn how to design, execute, and analyze experiments supporting Immuno-Oncology programs.
- Have the opportunity to participate in a wide range of research activities and get hands-on experience with assays such as primary cell isolation, cell culture, ELISA/MSD assays, cell-based functional assays, flow cytometry, and tissue processing for pharmacokinetic and pharmacodynamic studies.
- Present work to program teams and participate in department-wide meetings and discussions.
- Make meaningful contributions to a pivotal Immuno-Oncology program.
- Maintain a safe laboratory environment and follow all site safety and compliance requirements.
- Maintain an organized work area and electronic lab notebook.
Here's What You'll Need (Minimum Qualifications)
- Currently enrolled in a Bachelor's or Master's degree program in a STEM field (e.g., Biology, Biochemistry, Molecular Biology, Immunology, BioEngineering, or related discipline).
- Previous co-op experience is a plus
- Technical experience in the following areas is preferred: mammalian tissue culture, cell transfection, protein detection methods (MSD/ELISA), assay development and troubleshooting
- Prior experience in flow cytometry is a plus
- The candidate should be self-motivated and possess the desire to drive a project to completion.
- The co-op must be flexible and able to work in a fast-paced, team-oriented environment.
Here's What You'll Bring to the Table (Preferred Qualifications)
- GPA of 3.5 (on a 4.0 scale) or equivalent academic achievement.
- Demonstrated ability to work independently while contributing effectively within a team environment.
- Strong written and verbal communication skill.
- High attention to detail and commitment to quality and compliance.
- Interest in working within a rigorous, lab-based Immuno-Oncology department.
Requirements
- Currently enrolled in a Bachelor's or Master's degree program in a STEM field (e.g., Biology, Biochemistry, Molecular Biology, Immunology, BioEngineering, or related discipline)
- Self-motivated and desire to drive a project to completion
- Flexible and able to work in a fast-paced, team-oriented environment
- Technical experience in mammalian tissue culture, cell transfection, protein detection methods (MSD/ELISA), assay development and troubleshooting (preferred)
- Prior experience in flow cytometry (preferred)
- GPA of 3.5 (on a 4.0 scale) or equivalent academic achievement (preferred)
- Demonstrated ability to work independently while contributing effectively within a team environment (preferred)
- Strong written and verbal communication skill (preferred)
- High attention to detail and commitment to quality and compliance (preferred)
Benefits
- Meditation and mindfulness classes
- Subsidized commuter benefits
- Paid time off
- Vacation
- Sick time
- Holidays
- Volunteer days
- Year-end shutdown
- Location-specific perks
Company overview
Moderna, Inc. is a pioneering American biotechnology and pharmaceutical company headquartered in Cambridge, Massachusetts, that has revolutionized the field of medicine through its groundbreaking messenger RNA (mRNA) technology. Founded in 2010, the company has established itself as a global leader in RNA therapeutics, primarily focusing on mRNA vaccines and treatments. Moderna's innovative platform uses mRNA to provide cellular instructions for producing proteins that trigger immune responses, creating a new category of medicines with significant potential to improve patient outcomes across various therapeutic areas. The company gained worldwide recognition during the COVID-19 pandemic for developing one of the earliest and most effective mRNA vaccines, which demonstrated the transformative potential of its technology platform. Beyond infectious diseases, Moderna is advancing a diverse pipeline of 44 treatment and vaccine candidates across infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune conditions. With approximately 5,800 employees and a strong commitment to scientific innovation, Moderna continues to expand its manufacturing capabilities and research initiatives to deliver the greatest possible impact through mRNA medicines.